JP2010216917A - Ed評価方法 - Google Patents
Ed評価方法 Download PDFInfo
- Publication number
- JP2010216917A JP2010216917A JP2009062536A JP2009062536A JP2010216917A JP 2010216917 A JP2010216917 A JP 2010216917A JP 2009062536 A JP2009062536 A JP 2009062536A JP 2009062536 A JP2009062536 A JP 2009062536A JP 2010216917 A JP2010216917 A JP 2010216917A
- Authority
- JP
- Japan
- Prior art keywords
- glutathione
- subject
- concentration
- mild
- significantly higher
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 48
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 33
- 201000001881 impotence Diseases 0.000 claims abstract description 33
- 108010024636 Glutathione Proteins 0.000 claims abstract description 24
- 229960003180 glutathione Drugs 0.000 claims abstract description 23
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- PZAYJNNTMOGLPX-UHFFFAOYSA-N cyclopenta[c]pyrazole Chemical class N1=NC2=CC=CC2=C1 PZAYJNNTMOGLPX-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
【解決手段】 被験者の生体試料中のグルタチオン濃度を測定し、この濃度が健常者のグルタチオン濃度より有意に高い場合に、被験者の***不全(ED:erectile dysfunction)の程度が軽度であると評価する。
【選択図】 図1
Description
Claims (1)
- 被験者の生体試料中のグルタチオン濃度を測定し、この濃度が健常者のグルタチオン濃度より有意に高い場合に、被験者の***不全(ED:erectile dysfunction)の程度が軽度であると評価することを特徴とするED評価方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009062536A JP5208028B2 (ja) | 2009-03-16 | 2009-03-16 | Ed評価方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009062536A JP5208028B2 (ja) | 2009-03-16 | 2009-03-16 | Ed評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010216917A true JP2010216917A (ja) | 2010-09-30 |
JP5208028B2 JP5208028B2 (ja) | 2013-06-12 |
Family
ID=42975931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009062536A Expired - Fee Related JP5208028B2 (ja) | 2009-03-16 | 2009-03-16 | Ed評価方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5208028B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108519770B (zh) * | 2018-04-27 | 2020-10-27 | 东北大学 | 一种浮选过程运行控制的实验平台 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001507696A (ja) * | 1996-12-31 | 2001-06-12 | アンチオキシダント ファーマシューティカルズ コーポレーション | グルタチオンの医薬製剤およびその投与方法 |
JP2004131482A (ja) * | 2002-08-21 | 2004-04-30 | Chee Keung Chung | ガノデルマルシダム胞子を用いた抗老化/更年期症状緩和 |
WO2008106640A1 (en) * | 2007-03-01 | 2008-09-04 | Cedars-Sinai Medical Center | Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof |
-
2009
- 2009-03-16 JP JP2009062536A patent/JP5208028B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001507696A (ja) * | 1996-12-31 | 2001-06-12 | アンチオキシダント ファーマシューティカルズ コーポレーション | グルタチオンの医薬製剤およびその投与方法 |
JP2004131482A (ja) * | 2002-08-21 | 2004-04-30 | Chee Keung Chung | ガノデルマルシダム胞子を用いた抗老化/更年期症状緩和 |
WO2008106640A1 (en) * | 2007-03-01 | 2008-09-04 | Cedars-Sinai Medical Center | Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5208028B2 (ja) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Devaux et al. | Diagnostic and prognostic value of circulating micro RNA s in patients with acute chest pain | |
RU2713112C2 (ru) | Способы и средства для диагностики гриппа | |
Banne et al. | Reduced level of serum thiols in patients with a diagnosis of active disease | |
US20150355180A1 (en) | Differential Expression of Novel Protein Markers for the Diagnosis and Treatment of Eosinophilic Esophagitis | |
JP5330381B2 (ja) | 酸化還元電位(orp)を測定及び使用する方法 | |
Liu et al. | Prevalence and risk factors of CKD in Chinese patients with periodontal disease | |
Huang et al. | Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection | |
Goto et al. | Can wound exudate from venous leg ulcers measure wound pain status?: a pilot study | |
Busari et al. | Microalbuminuria and hypertensive retinopathy among newly diagnosed nondiabetic hypertensive adult Nigerians | |
Udy et al. | Point of care measurement of plasma creatinine in critically ill patients with acute kidney injury | |
JP6360848B2 (ja) | ライソゾーム病3疾患責任酵素の迅速マススクリーニング検査法 | |
JP5208028B2 (ja) | Ed評価方法 | |
Mahdavi-Mazdeh et al. | Comparison of serum neutrophil gelatinase-associated lipocalin (NGAL) with serum creatinine in prediction of kidney recovery after renal transplantation | |
Trueba et al. | Effects of academic exam stress on nasal leukotriene B4 and vascular endothelial growth factor in asthma and health | |
Nancey et al. | Urinary neopterin is a valuable tool in monitoring Crohn's disease activity | |
KR102281793B1 (ko) | 혈중 메타볼리즘을 이용한 건강 상태 정보 제공 장치 및 그 방법 | |
CN103344768B (zh) | 缺血性心脏病检测试剂盒及其应用 | |
KR20140013390A (ko) | 나노입자의 독성 평가방법 | |
Brady et al. | Cyanide-nitroprusside colorimetric assay: a rapid colorimetric screen for urinary cystine | |
Xie et al. | A preliminary study of the effects of the tilburg frailty indicator, frailty phenotype, and silver nanoparticle-silver needle therapy in senile inpatients with frailty | |
Dogra et al. | Intraoral biosensors: A promising diagnostic tool | |
US7759086B2 (en) | Diagnostic method for chronic fatigue syndrome by measuring elastase | |
RU2773830C1 (ru) | Способ диагностики расстройства вегетативной нервной системы у девочек дошкольного возраста, ассоциированного с избыточной контаминацией биосред детей марганцем | |
THALQUOTRA et al. | Association of Serum Beta-Trace Protein Levels in Patients with Chronic Kidney Disease: A Case-control Study. | |
Al-Mamouri et al. | Evaluation of total antioxidant capacity and total oxidant status in patients with COVID-19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121031 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130219 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160301 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |